GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Introduction/Background

Glycemic Efficacy of Liraglutide in the LEAD Trials

Blood Pressure Reduction With Liraglutide: LEADER Results

Lipid Characteristics of Patients After 24 Weeks of Treatment

Body Weight Reduction With Liraglutide: LEADER Results

LEADER Results: Hypoglycemia

GLP-1 RAs and Improved Cardiac Function

EMPA-REG: Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

LEADER: Primary Outcome Results*

LEADER: Results for CV Death

LEADER Subgroup Analysis: Effect of Liraglutide on Patients With T2DM and Polyvascular Disease

LEADER: Time to Composite Endpoint (Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death)

SUSTAIN-6 (Semaglutide): Primary Outcome Results

Despite Proven Advantages, Uptake of Newer Glucose-Lowering Agents Remains Low

Overcoming Patient Reluctance to Inject

Summary and Conclusions

Abbreviations

Abbreviations (cont)